These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3613754)

  • 21. Beneficial effects of oligotide, a novel oligodeoxyribonucleotide, in murine traumatic shock.
    Skurk C; Nuss C; Lefer AM
    Shock; 1995 Jan; 3(1):13-20. PubMed ID: 7531603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for a role of platelet activating factor in hypovolemic shock in the rat.
    Zingarelli B; Squadrito F; Bussolino F; Calapai G; Altavilla D; Ioculano M; Campo GM; Canale P; Caputi AP
    J Lipid Mediat Cell Signal; 1994 Mar; 9(2):123-34. PubMed ID: 8012759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective action of 6-keto-prostaglandin E1 in traumatic shock.
    Araki H; Lefer AM
    Prostaglandins Med; 1979 Apr; 2(4):277-84. PubMed ID: 575862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effect of a selective leukotriene antagonist in endotoxemia in the rat.
    Cook JA; Wise WC; Halushka PV
    J Pharmacol Exp Ther; 1985 Nov; 235(2):470-4. PubMed ID: 2997435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effects of a novel 21-aminosteroid during splanchnic artery occlusion shock.
    Johnson G; Lefer AM
    Circ Shock; 1990 Feb; 30(2):155-64. PubMed ID: 2311204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock.
    Aoki N; Siegfried M; Tsao P; Lento P; Lefer AM
    Res Commun Chem Pathol Pharmacol; 1988 Jun; 60(3):275-89. PubMed ID: 3175328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of a leukotriene antagonist on endotoxin-induced acute hemodynamic alterations.
    Etemadi AR; Tempel GE; Farah BA; Wise WC; Halushka PV; Cook JA
    Circ Shock; 1987; 22(1):55-63. PubMed ID: 3038364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of a neutral protease inhibitor in traumatic shock.
    Hock CE; Lefer AM
    Pharmacol Res Commun; 1985 Mar; 17(3):217-26. PubMed ID: 4011646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of a novel peptide leukotriene receptor antagonist, Ly-163443, in splanchnic artery occlusion shock.
    Bitterman H; Lefer AM
    Prostaglandins Leukot Essent Fatty Acids; 1988 May; 32(2):63-70. PubMed ID: 3406041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effects of a platelet activating factor (PAF) antagonist and its combined treatment with prostaglandin (PG) E1 in traumatic shock.
    Terashita Z; Stahl GL; Lefer AM
    J Cardiovasc Pharmacol; 1988; 12(5):505-11. PubMed ID: 2468048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time course of endothelial dysfunction and neutrophil adherence and infiltration during murine traumatic shock.
    Scalia R; Pearlman S; Campbell B; Lefer AM
    Shock; 1996 Sep; 6(3):177-82. PubMed ID: 8885082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.
    Aoki N; Lefer AM
    Methods Find Exp Clin Pharmacol; 1988 Jul; 10(7):413-8. PubMed ID: 3419244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of prostacyclin and taprostene in splanchnic artery occlusion shock.
    VanAntwerp DR; Hedley LR; Spires DA; Strosberg AM; Johnson G; Lefer AM
    Eicosanoids; 1991; 4(1):15-20. PubMed ID: 2059456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock.
    Lento PH; Saukkonen K; Aoki N; Lefer AM; Slivjak MJ; Smith EF
    Eur J Pharmacol; 1989 Jun; 165(2-3):241-9. PubMed ID: 2550251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):341-7. PubMed ID: 3116357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the splanchnic visceral organs in development of tolerance to traumatic shock.
    Araki H; Sollott SJ; Lefer AM
    J Trauma; 1980 Dec; 20(12):1046-51. PubMed ID: 7452749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of platelet-activating factor during traumatic shock.
    Stahl GL; Craft DV; Lento PH; Lefer AM
    Circ Shock; 1988 Nov; 26(3):237-44. PubMed ID: 3208421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of production of peptide leukotrienes in murine traumatic shock.
    Craft DV; Lefer DJ; Hock CE; Lefer AM
    Am J Physiol; 1986 Jul; 251(1 Pt 2):H80-5. PubMed ID: 3014907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhagic shock in cats.
    Freeman JG; Hock CE; Edmonds JS; Lefer AM
    J Pharmacol Exp Ther; 1984 Dec; 231(3):610-5. PubMed ID: 6094795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.